Combination therapy for autoimmune hypothyroidism

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of combining liothyronine (LT3) with levothyroxine (LT4) in patients suffering from autoimmune hypothyroidism who experience persistent tiredness despite normalized thyroid-stimulating hormone (TSH) levels on LT4 monotherapy. Patients will undergo a run-in period where they will switch to a standardized LT4 preparation to ensure stable TSH levels before being randomized to receive either LT3 or a placebo. The study aims to determine if the addition of LT3 can improve quality of life and alleviate symptoms in this patient population. Genetic factors related to thyroid hormone metabolism will also be considered in evaluating treatment responses.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with overt or subclinical primary hypothyroidism 18 years or older.\*
* LT4 monotherapy for at least 6 months.
* LT4 monotherapy dose of 75-225 microg, with at least a dose of 1.2 microg/kg.
* TSH levels within the assay-specific reference ranges for at least 3 months.
* Severe tiredness with a large negative impact on daily life for at least 6 months, with or without other persisting complaints. This is based on the patient's own experience, without judgment of the treating physician.
* Sufficiently fluent in Dutch and able to read Dutch.

  * Thyroid peroxidase (TPO) and/or thyroglobulin (Tg) antibody positivity is not a requirement as these have frequently not been determined. Instead, we ensure that we only include patients with autoimmune hypothyroidism by excluding other causes of hypothyroidism (see exclusion criteria).

Exclusion Criteria:

* Congenital hypothyroidism, hypothyroidism after (sub)acute thyroiditis\*, secondary (central) hypothyroidism
* Thyroid surgery, radioactive iodine treatment, or head and/or neck radiotherapy.
* Use of thyroid interfering drugs (current/past use of amiodarone, immunotherapy, tyrosin kinase inhibitors, interferon, or lithium and current use of oral or iv corticosteroids or dopamine).
* Current psychiatric disease treated at a "gespecialiseerde GGZ instelling"\*\*
* Clinical diagnosis of dementia.
* Pregnancy, breastfeeding or wish to become pregnant within 2 years.
* Women of reproductive age not using adequate contraception, who are not sterilized and do not have a sterilized partner. Adequate contraceptives include the contraceptive pill, patch, injection, implant, intrauterine device or system, vaginal ring, diaphragm or cap, and condom.
* Clinically relevant functional or structural abnormal heart (e.g., cardiomyopathy or valve disease)
* Recent acute coronary syndrome or unstable angina pectoris (\<4 weeks)
* Current/past atrial fibrillation
* Current conduction disorder on ECG (i.e, QRS\>120 ms or prolonged QTc (women≥460 ms and men≥450 ms)).
* Frequent ventricular extrasystole (=doublet, trigeminy, bigeminy or (non-sustained) ventricular tachycardia) in the past or on current ECG.
* Other obvious medical explanation for tiredness (e.g. end-stage renal disease, anemia, COPD stage IV, cancer, etc.)
* Other obvious major life event explanation for tiredness (e.g., mourning, loss of job)

  * Postpartum thyroiditis is not an exclusion criterium.
  * Treatments of mild non-complex psychological/psychiatric complaints are done in the " basis GGZ", e.g. consisting of conversations with a psychologist or psychotherapist, or via internet (e-health). "Gespecialiseerde GGZ" encompasses treatments of more severe psychological/psychiatric complaints. (link: Basis GGZ en gespecialiseerde GGZ \| Geestelijke gezondheidszorg (GGZ) \| Rijksoverheid.nl)

Where it's running

• Flevoziekenhuis
  Almere Stad, Netherlands Recruiting
• Amsterdam UMC - Location AMC
  Amsterdam, Netherlands Recruiting
• Rijnstate
  Arnhem, Netherlands Recruiting
• Amphia ziekenhuis
  Breda, Netherlands Recruiting
• Van Weel-Bethesda Hospital
  Dirksland, Netherlands Recruiting
• Albert Schweitzer Hospital
  Dordrecht, Netherlands Recruiting

Study contacts

• Principal investigator: Marco Medici, MD PhD — Erasmus Medical Center
• Study coordinator: Marco Medici, MD PhD
• Email: m.medici@erasmusmc.nl
• Phone: +31107043415

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SYMmetric Valve expansion to reduce hypoattenuated leaflet thickening after balloon-expandable TAVI

  This trial tests whether the Double-TAP post-dilatation strategy can reduce HALT and improve valve function in patients 70 or older undergoing balloon-expandable TAVI.

  Recruiting Erasmus Medical Center · Düsseldorf and 4 other locations · NCT07872020

• External warming to help septic patients without fever

  We’re testing whether warming the body externally can help people with sepsis who don’t have a fever.

  Recruiting Erasmus Medical Center · Rotterdam, South Holland · NCT07831057

• Personalized AI Education Avatar for cancer treatment information

  A digital avatar using AI-delivered educational videos helps adults starting new cancer treatments learn about their plan and side effects, with patient-friendly guidance and nurse support as needed.

  Recruiting Erasmus Medical Center · Rotterdam · NCT07715981

• Turbine-based CO2 Insufflator in Pediatric Laparoscopy

  A new turbine-powered CO2 insufflator is being tested in children to see if it can maintain steadier abdominal pressures during laparoscopic surgery.

  Recruiting Erasmus Medical Center · Rotterdam, South Holland · NCT07715968

• Guideline Adherence in HFrEF: See If Mirror Information Helps Doctors and Patients Follow GDMT

  This study tests whether showing doctors, or both doctors and patients, mirror information about how well guideline-directed medical therapy is being used in heart failure with reduced ejection fraction.

  Recruiting Erasmus Medical Center · Rotterdam · NCT07702760

• Mild heat therapy added to standard treatment for locally advanced head and neck cancer

  This early-stage trial tests whether mild hyperthermia can be safely added to standard radiotherapy with or without chemotherapy for locally advanced head and neck cancer.

  Recruiting Phase 1 Erasmus Medical Center · Rotterdam, South Holland · NCT07690618

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.